Engitix Therapeutics Revenue and Competitors

London,

Location

$60.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Engitix Therapeutics's estimated annual revenue is currently $5.2M per year.(i)
  • Engitix Therapeutics's estimated revenue per employee is $77,500
  • Engitix Therapeutics's total funding is $60.4M.

Employee Data

  • Engitix Therapeutics has 67 Employees.(i)
  • Engitix Therapeutics grew their employee count by -19% last year.

Engitix Therapeutics's People

NameTitleEmail/Phone
1
Co-Founder and CEOReveal Email/Phone
2
COOReveal Email/Phone
3
VP Oncology and Immuno-OncologyReveal Email/Phone
4
Director Medicinal ChemistryReveal Email/Phone
5
Director, Computational BiologyReveal Email/Phone
6
Director BiologyReveal Email/Phone
7
Senior Director, Drug Development & OperationsReveal Email/Phone
8
Senior Director, Intellectual PropertyReveal Email/Phone
9
Director, FibrosisReveal Email/Phone
10
Liver fibrosis progamme leader and Director Translational BiologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Engitix Therapeutics?

To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.

keywords:N/A

$60.4M

Total Funding

67

Number of Employees

$5.2M

Revenue (est)

-19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Engitix Therapeutics News

2022-04-13 - Billionaire Platt-Backed Engitix Inks $300 Million Takeda Deal

Engitix, whose backers include billionaire hedge fund manager Michael Platt, will work with Takeda to jointly develop novel therapeutics for...

2022-04-13 - With $300M up for grabs, Engitix helps Takeda dig into ...

The company focuses on neuroscience and immuno-oncology medicines, and its current pipeline includes therapeutics for patients with...

2022-04-13 - Engitix Announces Expanded Collaboration and Licensing ...

... Agreement with Takeda for the discovery and development of novel therapeutics for inflammatory bowel disease (IBD) builds on existing...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.2M67-67%N/A
#2
$8.7M67-41%N/A
#3
$8.4M6731%N/A
#4
$13.7M6716%N/A
#5
$13.3M67-14%N/A